A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Phase 3

Completed

• Conditions: Relapsed or Refractory Multiple Myeloma
• Interventions: Drug: Lenalidomide; Drug: dexamethasone

• Registration Number: NCT00478777
• Lead Sponsor: Celgene Corporation

Brief Summary

This was a multicenter, open-label, single-arm phase 3B study of the combination lenalidomide plus pulse high-dose dexamethasone.

This study (CC-5013-MM-019) was set up and executed primarily as an expanded access program in Germany.

Screening procedures were to take place within 28 days prior to Cycle 1 Day 1 (baseline) with the exception of hematology assessments that were to be performed within 14 days prior to Cycle 1 Day 1. Randomization, blinding, and stratification were not applied in this open-label single-arm study.

Eligible subjects given open-label treatment and received treatment with lenalidomide plus high-dose dexamethasone in 28-day cycles.

Lenalidomide (hard capsules) was to be administered orally (PO) at a dose of 25 mg daily (QD) for the first 21 days of each 28-day cycle. According to the protocol, accrual of subjects to the study was to be terminated within 2 months of commercial availability of lenalidomide for this indication in Germany.

Upon discontinuation from study, minimal information was collected in order to identify when disease progressed.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-03
• Study First Submitted: 2007-05-23
• Study First Submitted QC: 2007-05-24
• Study First Posted: 2007-05-25
• Primary Completion: 2007-11
• Study Completion: 2009-08
• Status Verified: 2011-09
• Results First Submitted: 2011-09-26
• Results First Submitted QC: 2011-09-26
• Last Update Submitted: 2011-09-26
• Results First Posted: 2011-11-03
• Last Update Posted: 2011-11-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• Must understand and voluntarily sign an informed consent form.
• Must be ≥18 years of age at the time of signing the informed consent form.
• Must be able to adhere to the study visit schedule and other protocol requirements.
• Must be diagnosed with multiple myeloma that is progressing after at least 2 cycles of anti-myeloma treatment or that has relapsed with progressive disease after treatment.
• Subjects may have been previously treated with thalidomide and/or radiation therapy. In addition, radiation therapy initiated prior to or at baseline (Day 1) may be given concurrently with study therapy, provided that all other eligibility criteria are satisfied.
• Subjects must discontinue all anti-myeloma drug or non-drug therapy prior to the first dose of study drug with the exception of radiation therapy initiated prior to or at baseline (Day 1).
• Measurable levels of myeloma paraprotein in serum (>0.5 g/dL) or urine (>0.2 g excreted in a 24-hour collection sample).
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
• Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; and 3) for at least 28 days after discontinuation from the study.

Exclusion Criteria

• The presence of any of the following will exclude a subject from study enrollment:

• Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.

• Pregnant or lactating females.

• Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.

• Any of the following laboratory abnormalities:

  • Absolute neutrophil count (ANC) <1,000 cells/mm^3 (1.0 x 10^9/L)
  • Platelet count <75,000/mm^3 (75 x 109/L) for subjects in whom <50% of the bone marrow nucleated cells are plasma cells.
  • Platelet count <30,000/mm^3 (30x10^9/L) for subjects in whom ≥50% of bone marrow nucleated cells are plasma cells.
  • Serum creatinine >2.5 mg/dL (221 µmol/L)
  • Serum SGOT/AST or SGPT/ALT >3.0 x upper limit of normal (ULN)
  • Serum total bilirubin >2.0 mg/dL (34 µmol/L)

• Prior history of malignancies other than multiple myeloma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for ≥1 year.

• Prior history of stroke and/or thromboembolic event

• Known hypersensitivity to thalidomide or dexamethasone.

• Prior history of uncontrollable side effects to dexamethasone therapy.

• The development of a desquamating rash while taking thalidomide.

• Neuropathy ≥ Grade 2.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
lenalidomide plus dexamethasone	Lenalidomide	Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), dexamethasone was to be reduced to 40 mg QD for Days 1-4 of each 28 day-cycle.
lenalidomide plus dexamethasone	dexamethasone	Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), dexamethasone was to be reduced to 40 mg QD for Days 1-4 of each 28 day-cycle.

Primary Outcome Measures

Name	Time	Method
Kaplan Meier Estimate for Time to Disease Progression	up to 827 days	Time to disease progression (TTP) was based on the European Group for Blood and Marrow Transplantation (EBMT) myeloma response determination criteria developed by Bladé (Bladé, 1998). TTP is a Kaplan Meier estimate of the time from randomization to the first documentation of progressive disease.; Progressive disease based on increasing monoclonal paraprotein levels require a confirmatory value one week apart. Disease progression can also be based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.

Secondary Outcome Measures

Name	Time	Method
Participant's Best Overall Response Based on the European Group for Blood and Marrow Transplantation (EBMT) Myeloma Response Criteria	Up to 827 days	Best overall response was calculated as the best assessment from all cycles (including treatment discontinuation visit) and follow-up. The response rate was summarized as complete response (CR), partial response (PR), stable disease (SD), progression (PD), response not evaluable, and derived categories (PR+CR) and (PR+CR+SD).; CR is negative immunofixation on both serum and urine maintained for 6 weeks straight. PR is a 50% decrease in serum paraprotein maintained for 6 weeks straight. SD is serum paraprotein values within 25% of baseline.
Participants With Treatment-emergent Adverse Experiences (TEAEs)	up to 8 months	Counts of study participants who had treatment-emergent adverse events (TEAEs) defined as any reported AE that started on or after the first day of study drug dosing. A participant with multiple occurrences of an adverse event within a category is counted only once in that category.; National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) was used by investigators to assess TEAEs. Severity scale ranges from 0 (none) to 5 (death). Grade 3=severe AE; Grade 4=life threatening or disabling AE; Grade 5=death.
Time to Partial Response Based on the European Group for Blood and Marrow Transplantation (EBMT) Myeloma Response Determination Criteria	up to 827 days	Time to partial response is the time from randomization to a 50% decrease in serum paraprotein maintained for six weeks straight. This was determined by free light chain concentrations which were taken every two weeks during the treatment phase of the trial.

Trial Locations

Locations (48)

Abt. Innere Medizin I , Hämatologie / Onkologie, Universitätsklinikum Freiburg; 🇩🇪 Freiburg, Germany

EPS - Early Phase Solutions GmbH; 🇩🇪 Jena, Germany

Direktor der Klinik f. Hämatologie, Universitätsklinikum Essen; 🇩🇪 Essen, Germany

Klinik für Innere Medizin, Klinikum Frankfurt (Oder) GmbH; 🇩🇪 Frankfurt (Oder), Germany

Interne Klinik Dr. Argirov, Schön-Kliniken; 🇩🇪 Burg, Germany

II. Medizinische Abteilung, Asklepios Klinikum Altona; 🇩🇪 Hamburg, Germany

Universitätsklinikum EssenInnere Klinik und Poliklinik; 🇩🇪 Essen, Germany

Medizinische Klinik II (ZIM),Hämatologie / Onkologie Uniklinik Frankfurt; 🇩🇪 Frankfurt am Main, Germany

Klinikum Mannheim der Universität Heidelberg; 🇩🇪 Mannheim, Germany

Medizinische Klinik III Klinikum der Universität München-Großhadern; 🇩🇪 München, Germany

Klinikum der Universität Regensburg; 🇩🇪 Regensburg, Germany

Abteilung Hämatologie und Onkologie, Medizinische Fakultät der Universität Rostock; 🇩🇪 Rostock, Germany

Universitätsklinikum GöttingenHamatologie und Onkologie; 🇩🇪 Göttingen, Germany

Abt. Hämatologie, Hämatologie und Onkologie, Medizinische Hochschule Hannover; 🇩🇪 Hannover, Germany

Medizinische Klinik und Poliklinik V Universitaetsklinikum Heidelberg; 🇩🇪 Heidelberg, Germany

Klinik für Innere Medizin II Hämatologie / Onkologie Universitätsklinikum Jena; 🇩🇪 Jena, Germany

Hämatologie / Onkologie / Infektionskrankheiten, Palliativmedizin Städtisches Klinikum Karlsruhe; 🇩🇪 Karlsruhe, Germany

2. Med. Klinik , Sektion f. Stammzell- + Immuntherapie Universitätsklinikum Schleswig-Holstein; 🇩🇪 Kiel, Germany

Klinik f. Innere Medizin, Klinikum der Universität zu Köln; 🇩🇪 Köln, Germany

Med. Klinik 1, Helios Klinikum Wuppertal; 🇩🇪 Wuppertal, Germany

Medizinische Klinik und Poliklinik II Abt. Hämatologie / Onkologie, Universitätsklinikum Leipzig AÖR; 🇩🇪 Leipzig, Germany

III. Med. Klinik, Johannes Gutenberg Universität; 🇩🇪 Mainz, Germany

Med. Klinik III , St. Marienkrankenhaus Siegen; 🇩🇪 Siegen, Germany

Caritasklinik St. Theresia; 🇩🇪 Saarbrucken, Germany

ms² Medizinische Statistik Saarbrücken; 🇩🇪 Saarbrucken, Germany

Zentrum für Innere Medizin II Robert- Bosch-Krankenhaus GmBH; 🇩🇪 Stuttgart, Germany

Krankenanstalt Mutterhaus der Borromäerinnen; 🇩🇪 Trier, Germany

Praxis Dres. Maintz & GroschekHämatologie / Onkologie; 🇩🇪 Wuerselen, Germany

Poliklinik I, Hämatologie/ Onkologie, Universitätsklinikum Bonn; 🇩🇪 Bonn, Germany

Medizinische Klinik und Poliklinik II der Charité Universitätsmedizin Berlin Campus Mitte; 🇩🇪 Berlin, Germany

Johanniter-Krankenhaus Bonn Friedrich-Wilhelm-Stift gGmbH; 🇩🇪 Bonn, Germany

Medizinische Klinik Städtisches Klinikum Braunschweig gGmbH; 🇩🇪 Braunschweig, Germany

Klinik für Innere Medizin III Klinikum Chemnitz gGmbH; 🇩🇪 Chemnitz, Germany

Universitaetsklinikum Dusseldorf Klinik fuer Haematologie; 🇩🇪 Düsseldorf, Germany

Medizinische Klinik und Poliklinik, Uniklinikum Dresden; 🇩🇪 Dresden, Germany

Medizinische Klinik und Poliklinik A, Universitätsklinikum Münster; 🇩🇪 Münster, Germany

Fachärzte für Innere Medizin Hämatologie und Onkologie Gemeinschaftspraxis; 🇩🇪 Münster, Germany

Abteilung Hämatologie und Onkologie, Hämatologie und Onkologie, Medizinische Klinik, Klinikum Ernst v. Bergmann; 🇩🇪 Potsdam, Germany

Med. Klinik u. Poliklinik IIKlinikum der Universität Würzburg; 🇩🇪 Würzburg, Germany

Abt. II Hämatologie, Onkologie und Immunologie Medizinische Klinik Abt.II; 🇩🇪 Tübingen, Germany

Interdisziplinäre Klinik und Poliklinik für Stammzellentransplantation Universitätsklinik Hamburg - Eppendorf; 🇩🇪 Hamburg, Germany

Ärzte f. Innere Medizin Gemeinschaftspraxis f. Hämatologie u. Onkologie; 🇩🇪 Köln, Germany

Onkologie Praxis Oldenburg; 🇩🇪 Oldenburg, Germany

Institut für Versorgungsforschung in der Onkologie Praxisklinik für Hämatologie und Onkologie; 🇩🇪 Koblenz, Germany

Abt. Onkologie/ Hämatologie, Klinikum Oldenburg; 🇩🇪 Oldenburg, Germany

Hämatologisch-onkologische Praxis; 🇩🇪 Würzburg, Germany

Hämatologisch-Onkologisches Institut für medizinische Service Leistungen; 🇩🇪 Mönchengladbach, Germany

Medizinische Universitätsklinik; 🇩🇪 Ulm, Germany